These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 34232253)

  • 1. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
    Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
    JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis.
    Ederhy S; Fenioux C; Cholet C; Rouvier P; Redheuil A; Cohen A; Salem JE
    Can J Cardiol; 2021 Oct; 37(10):1654-1656. PubMed ID: 33373722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
    Vasbinder A; Ismail A; Salem JE; Hayek SS
    Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
    Munir AZ; Gutierrez A; Qin J; Lichtman AH; Moslehi JJ
    Nat Rev Cancer; 2024 Aug; 24(8):540-553. PubMed ID: 38982146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
    Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
    Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
    Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
    J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
    Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
    Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
    Nielsen DL; Juhl CB; Nielsen OH; Chen IM; Herrmann J
    JAMA Oncol; 2024 Oct; 10(10):1390-1399. PubMed ID: 39172480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
    Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
    BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.
    Coustal C; Vanoverschelde J; Quantin X; Lesage C; Michot JM; Lappara A; Ederhy S; Assenat E; Faure M; Issa N; Lambotte O; Puyade M; Dereure O; Tosi D; Rullier P; Serre I; Larcher R; Klouche K; Chanques G; Vernhet-Kovacsik H; Faillie JL; Agullo A; Roubille F; Guilpain P; Maria ATJ
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review.
    Tedeschi A; Camilli M; Ammirati E; Gentile P; Palazzini M; Conti N; Verde A; Masciocco G; Foti G; Giannattasio C; Garascia A
    Future Cardiol; 2023 Feb; 19(2):91-103. PubMed ID: 37078438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management.
    Gürdoğan M; Yalta K
    Anatol J Cardiol; 2020 Aug; 24(2):68-75. PubMed ID: 32749254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis.
    Drobni ZD; Zafar A; Zubiri L; Zlotoff DA; Alvi RM; Lee C; Hartmann S; Gilman HK; Villani AC; Nohria A; Groarke JD; Sullivan RJ; Reynolds KL; Zhang L; Neilan TG
    J Am Heart Assoc; 2020 Dec; 9(23):e018306. PubMed ID: 33190570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
    Thavendiranathan P; Zhang L; Zafar A; Drobni ZD; Mahmood SS; Cabral M; Awadalla M; Nohria A; Zlotoff DA; Thuny F; Heinzerling LM; Barac A; Sullivan RJ; Chen CL; Gupta D; Kirchberger MC; Hartmann SE; Weinsaft JW; Gilman HK; Rizvi MA; Kovacina B; Michel C; Sahni G; González-Mansilla A; Calles A; Fernández-Avilés F; Mahmoudi M; Reynolds KL; Ganatra S; Gavira JJ; González NS; García de Yébenes Castro M; Kwong RY; Jerosch-Herold M; Coelho-Filho OR; Afilalo J; Zataraín-Nicolás E; Baksi AJ; Wintersperger BJ; Calvillo-Arguelles O; Ederhy S; Yang EH; Lyon AR; Fradley MG; Neilan TG
    J Am Coll Cardiol; 2021 Mar; 77(12):1503-1516. PubMed ID: 33766256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Palaskas NL; Segura A; Lelenwa L; Siddiqui BA; Subudhi SK; Lopez-Mattei J; Durand JB; Deswal A; Zhao B; Maximilian Buja L; Iliescu C
    Eur J Heart Fail; 2021 Oct; 23(10):1725-1735. PubMed ID: 34114291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
    Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
    Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
    Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
    Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
    Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
    J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.